JW LifescienceJW생명과학

JW Lifescience shows steady profitability on a shrinking-price, low-valuation basis, with the share price down over the past year.

The company makes IV fluids and related pharmaceuticals, selling mainly to affiliate JW Pharmaceutical and other B2B buyers, with some exports. Trailing revenue to H1 2026 is about ₩254B with an operating margin of 13.1% and a net margin of 12.7%. At ₩10,500, the shares trade at about 5.2 times earnings and 0.7 times book, and are down 21.6% over one year.

What stands out

• Revenue grew 15.9% in 2025 to about ₩258B, but operating income was roughly flat at ₩33B and net income fell from ₩44B in 2024 to ₩29B.
• Trailing free cash flow is about ₩36B against cash of ₩9B and borrowings of ₩30.5B, with liabilities at 34.8% of equity.
• The filings list a corporate value-up plan (March 2026), a 5%+ holding report (July 2026), and preliminary earnings and a half-year report in August 2026.
• The DCF-based fair value model gives a base of ₩38,089, a bear case of ₩23,304 and a bull case of ₩63,176, all of which are model outputs rather than forecasts.
• Foreign ownership is unchanged at 14.4% over 60 days, and 20-day flows show net foreign and institutional selling against net retail buying.

What to watch

• Q3 2026 results and any update to the value-up plan, which the filings do not detail in this data.
• Whether borrowings and the decline in net income from 2024 stabilise, given the lower 2025 earnings base.
• The Baxter licensing and supply arrangement and export exposure, for which the data gives no current terms or timing.